Does the Cervical Cancer Vaccine (Gardasil) Protect Women Over 18 Against Cancer?

Research published in the Journal of Clinical Oncology suggests the HPV (human papillomavirus) vaccine Gardasil, also called Gardisil or Silgard, may not protect many women, particularly those over 18 or with abnormal cellular findings, against high-grade squamous intraepithelial lesions (structural and functional disorders caused by cancer) and second-degree dysplasia.
HPV is among the most common sexually transmitted diseases and occurs in sexually active women of all ages. It is most frequent at 52, with other commonly recorded age ranges 35-39 and 60-64. Studies since the 1970s identified over 100 types. It attaches to areas such as cervix, vulva, vagina, anus and penis and causes cancer. It is therefore present in almost all cervical cancers, among the world's second-ranking and our country's leading gynecological cancers.
Gardasil, a quadrivalent recombinant vaccine against cancer-associated HPV types 6,11,16,18, is one of two vaccines approved by the American drug authority against cervical cancer-related HPV. Approved for women aged 9-26, it is recommended before sexual activity at 11-12.
University of Manitoba researchers evaluated protection between September 2006 and April 2010 in women older than 15, numbering over 13,000. Of them, 3,541 had Gardasil and 9,594 were age-matched unvaccinated controls. Researchers assessed estimated risks for atypical squamous cells, low-grade and high-grade squamous intraepithelial lesions.
Among ages 15-17, the vaccine reduced high-grade SIL risk by %35 and low-grade SIL by %21; the atypical squamous cell value was %1. Estimates increased among women with at least one Pap smear after data recording: high-grade SIL %46, low-grade %35 and atypical cells %23.
Protection was lower at 18 and above. Among those without abnormal cellular findings, high-grade SIL fell %23; no protection was found in those with abnormalities.
In conclusion, Gardasil was not highly effective against high-grade SIL or second-degree dysplasia particularly in those with pre-vaccination abnormalities or vaccinated above 18.
The study emphasizes vaccination early, before HPV exposure. Not everyone with HPV develops cancer, but medical checks 1-2 times yearly are one precaution supporting healthy life.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.